Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles
Open Access
- 1 July 2015
- journal article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 10, 4565-4580
Abstract
Current colon-targeted drug-delivery approaches for colitis therapy often utilize single pH-triggered systems, which are less reliable due to the variation of gut pH in individuals and in disease conditions. Herein, we prepared budesonide-loaded dual-sensitive nanoparticles using enzyme-sensitive azo-polyurethane and pH-sensitive methacrylate copolymer for the treatment of colitis. The therapeutic potential of the enzyme/pH dual-sensitive nanoparticles was evaluated using a rat colitis model and compared to single pH-triggered nanoparticles. Clinical activity scores, colon/body weight ratios, myeloperoxidase activity, and proinflammatory cytokine levels were markedly decreased by dual-sensitive nanoparticles compared to single pH-triggered nanoparticles and budesonide solution. Moreover, dual-sensitive nanoparticles accumulated selectively in inflamed segments of the colon. In addition, dual-sensitive nanoparticle plasma concentrations were lower than single pH-triggered nanoparticles, and no noticeable in vitro or in vivo toxicity was observed. Our results demonstrate that enzyme/pH dual-sensitive nanoparticles are an effective and safe colon-targeted delivery system for colitis therapy.Keywords
This publication has 31 references indexed in Scilit:
- Drug delivery strategies in the therapy of inflammatory bowel diseaseAdvanced Drug Delivery Reviews, 2014
- Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel diseaseProceedings of the National Academy of Sciences, 2013
- Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II studyGut, 2013
- Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I StudyGastroenterology, 2012
- 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trialJournal of Crohn's and Colitis, 2011
- Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's DiseaseGastroenterology, 2011
- Budesonide for induction of remission in Crohn's disease2008
- Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseasesProceedings of the National Academy of Sciences, 2007
- New oral delivery systems for treatment of inflammatory bowel diseaseAdvanced Drug Delivery Reviews, 2005
- Development of an Oral Drug Delivery System Targeting Immune-Regulating Cells in Experimental Inflammatory Bowel Disease: A New Therapeutic StrategyThe Journal of Pharmacology and Experimental Therapeutics, 2000